Farmas USA

+13% con 22k shares, VAMOSSSSS
CLSN

edito: a tomar por saco, ya llego la maquinita, ha empezado a meter paquetitos de 100 shares y de 1,38 la ha bajado a 1.30 ... :((((

Lo curioso es que este premarket es post- conferencia, que ya termino a las 11:30-12:00 ...

LAWRENCEVILLE, N.J., June 20, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ:CLSN) announced today that Professor Riccardo Lencioni, MD, FSIR, EBIR, 2013 ECIO Program Co-Chairman and the Director of the Division of Diagnostic Imaging and Intervention at Pisa University School of Medicine in Italy and Lead European Principal Investigator for the HEAT Study reviewed the clinical trial results from the Company's Phase III HEAT Study including findings from the HEAT Study post-hoc analysis at the 2013 European Conference on Interventional Oncology, which is being held June 19-22, 2013 in Budapest, Hungary. The emerging post-hoc findings suggest that the heating cycles can be optimized to markedly improve radiofrequency ablation (RFA) when used with ThermoDox®. The post-hoc data indicates that ThermoDox® may provide potential for clinically relevant improved progression free survival (PFS) and Overall Survival (OS) outcomes. Professor Lencioni made two presentations on hepatocellular carcinoma (HCC) and related advances in interventional management.
"I am pleased to present this post-hoc analysis of a large subgroup of patients from the Phase III HEAT Study to the European and international interventional oncology community which may be indicating a meaningful clinical benefit in both progression free survival (PFS) and overall survival (OS) in patients who received an optimized RFA procedure," said Professor Lencioni. "It is important to note the duration of heat from the RFA procedure is a key factor in a successful clinical outcome when combined with ThermoDox®. These findings are consistent with our understanding that increased perfusion and associated heating time are important factors for ensuring that the heat-sensitive liposomes are activated to deposit high concentrations of doxorubicin in the tumor and the surrounding liver tissue."

http://investor.celsion.com/releasedetail.cfm?ReleaseID=772645

LO QUE YA NO SE SI ESTO ES MAS DE LO MISMO O HAY ALGUN DATO NUEVO

De momento está sirviendo para tener un buen premkt. La duda es si esto hará que suba a los niveles cercanos a los $2 o se quedará en esto.

Ahora mismo 1.44$ subiendo un 18%

CLSN

1.49!! y 170.000 shares y aun queda 1h hasta apertura!

Destroza esa resistencia vamosssss

CLSN

300k shares en premarket ... esto ya es volumen, señores.
CLSN

ZLCS
Para la atención de los "zalicusianos", parece que hoy nos va a dar una alegría, a ver si es verdad y no se baja al final de jornada.

http://www.dailyfinance.com/2013/06/19/zalicus-publishes-data-on-selective-estrogen-recep/

https://www.google.com/finance?q=NASDAQ%3AZLCS&ei=TwDDUbm3H-fCwAOsnAE